Davierwala Piroze M, Borger Michael A, David Tirone E, Rao Vivek, Maganti Manjula, Yau Terrence M
Division of Cardiovascular Surgery, Toronto General Hospital, University Health Network, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
J Thorac Cardiovasc Surg. 2006 Feb;131(2):329-35. doi: 10.1016/j.jtcvs.2005.09.022.
Reoperations on aortic valves are associated with increased mortality, which may affect valve prosthesis selection at the time of initial aortic valve replacement. We analyzed our experience to determine whether reoperation itself independently predicts mortality during aortic valve surgery.
Demographic, intraoperative, and outcome data were collected prospectively on patients undergoing primary or redo aortic valve replacement or Bentall procedures after previous aortic valve replacement with or without concomitant coronary bypass grafting at a single institution from 1990 through 2002. Logistic regression analyses validated by means of bootstrap methodology identified the predictors of hospital mortality and the independent effect of reoperation.
Of 2673 patients undergoing aortic valve surgery, 2375 were primary operations, 216 were reoperations, and 82 were Bentall-after-aortic valve replacement procedures. Of 298 reoperations, 32 were third and 5 were fourth procedures. Mortality was 2.3% for primary operations, 4.6% for redo aortic valve replacement, and 2.4% for Bentall-after-aortic valve replacement procedures. Most patients underwent elective procedures, with mortalities of 1.6%, 1.7%, and 2.5%, respectively. Hospital mortality was independently predicted by peripheral vascular disease (odds ratio, 3.6), active endocarditis (odds ratio, 2.9), worsening New York Heart Association class (odds ratio, 2.3), and need for annular enlargement (odds ratio, 2.1). Reoperation itself did not predict hospital mortality.
The risk of mortality during aortic valve surgery is due mostly to active endocarditis, New York Heart Association class, and comorbidity. We failed to find a significant effect of reoperation on perioperative mortality. Mechanical valves, with their attendant anticoagulation-related morbidity, should not be implanted solely because of anticipated high mortality associated with bioprosthetic rereplacement.
主动脉瓣再次手术与死亡率增加相关,这可能会影响初次主动脉瓣置换时瓣膜假体的选择。我们分析了我们的经验,以确定再次手术本身是否能独立预测主动脉瓣手术期间的死亡率。
前瞻性收集1990年至2002年在单一机构接受初次或再次主动脉瓣置换或在先前主动脉瓣置换后进行Bentall手术(伴或不伴同期冠状动脉搭桥术)患者的人口统计学、术中及结局数据。通过自助法验证的逻辑回归分析确定了医院死亡率的预测因素以及再次手术的独立影响。
在2673例接受主动脉瓣手术的患者中,2375例为初次手术,216例为再次手术,82例为主动脉瓣置换后Bentall手术。在298例再次手术中,32例为第三次手术,5例为第四次手术。初次手术的死亡率为2.3%,再次主动脉瓣置换的死亡率为4.6%,主动脉瓣置换后Bentall手术的死亡率为2.4%。大多数患者接受择期手术,死亡率分别为1.6%、1.7%和2.5%。医院死亡率的独立预测因素为外周血管疾病(比值比,3.6)、活动性心内膜炎(比值比,2.9)、纽约心脏协会分级恶化(比值比,2.3)以及需要扩大瓣环(比值比,2.1)。再次手术本身并不能预测医院死亡率。
主动脉瓣手术期间的死亡风险主要归因于活动性心内膜炎、纽约心脏协会分级以及合并症。我们未发现再次手术对围手术期死亡率有显著影响。不应仅因预计生物假体再次置换相关的高死亡率而植入机械瓣膜及其伴随的抗凝相关并发症。